Alpha 2.0
Login Register
» Authors » Alan M McGregor

Alan M McGregor

Explore the profile of Alan M McGregor including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 68
Followers 0
Related Specialties
Microbiology
Endocrinology
General Medicine
Top 10 Co-Authors
Justen Manasa
Vinie Kouamou
Chiratidzo E Ndhlovu
David Katzenstein
Prakash V Rao
J Paul Banga
Jacqueline A Gilbert
Tariro Makadzange
Tarisiro Matiza
Rebecca A Lyall
Published In
J Clin Microbiol
Endocrinology
AIDS
J Immunol
Clin Endocrinol (Oxf)
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction for Kouamou et al., "Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries"
Kouamou V, Manasa J, Katzenstein D, McGregor A, Ndhlovu C, Makadzange T
J Clin Microbiol . 2022 Jun; 60(7):e0070822. PMID: 35695562
No abstract available.
2.
Compartmentalized T cell profile in the lungs of patients with HIV-1-associated pulmonary Kaposi sarcoma
Matiza T, Boyd K, Lyall R, Kwon D, McGregor A, Fiorillo S, et al.
Medicine (Baltimore) . 2021 Dec; 100(51):e28328. PMID: 34941134
Pulmonary Kaposi sarcoma (pKS) caused by Human herpesvirus 8 (HHV-8) is a devastating form of KS in patients with advanced acquired immunodeficiency syndrome (AIDS) and is associated with increased morbidity...
3.
Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries
Kouamou V, Manasa J, Katzenstein D, McGregor A, Ndhlovu C, Makadzange T
J Clin Microbiol . 2020 Jun; 58(9). PMID: 32522826
HIV drug resistance (HIVDR) is a barrier to sustained virologic suppression in low- and middle-income countries (LMICs). Point mutation assays targeting priority drug resistance mutations (DRMs) are being evaluated to...
4.
Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy
Kouamou V, Manasa J, Katzenstein D, McGregor A, Ndhlovu C, Makadzange A
AIDS . 2019 Jul; 33(11):1729-1737. PMID: 31361272
Objectives: The integrase strand inhibitor dolutegravir (DTG) combined with tenofovir and lamivudine (TLD) is a single tablet regimen recommended for 1st, 2nd and 3rd-line public health antiretroviral therapy (ART). We...
5.
Determining the utility of the 60 min cortisol measurement in the short synacthen test
Chitale A, Musonda P, McGregor A, Dhatariya K
Clin Endocrinol (Oxf) . 2012 Jul; 79(1):14-9. PMID: 22747889
Objective: Despite the widespread use of the short synacthen test (SST), there remains no clear consensus on sampling times for the measurement of serum cortisol that best determines adrenal reserve....
6.
Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways
Gilbert J, Gianoukakis A, Salehi S, Moorhead J, Rao P, Khan M, et al.
J Immunol . 2006 Apr; 176(8):5084-92. PMID: 16585606
The thyroid target Ag for disease-inducing autoantibodies in Graves' disease is the receptor for thyroid-stimulating hormone (TSH), but little is known about the molecular basis of this pathogenic Ab response....
7.
Dynamics of thyroid-stimulating and -blocking antibodies to the thyrotropin receptor in a murine model of Graves' disease
Muehlberg T, Gilbert J, Rao P, McGregor A, Banga J
Endocrinology . 2004 Feb; 145(4):1539-45. PMID: 14764633
Graves' disease is characterized by the presence of autoantibodies to the TSH receptor (TSHR). There are multiple antibodies to the TSHR, with thyroid-stimulating antibodies (TSAbs) and TSH-stimulating blocking antibodies (TSBAbs),...